Search results
MRE-liver stiffness measure better for varices in NAFLD cirrhosis
Medical Xpress· 3 days agoFor patients with obesity and nonalcoholic fatty liver disease (NAFLD) compensated cirrhosis (CC),...
Mouse study shows intermittent fasting protects against liver inflammation and liver cancer
Medical Xpress· 4 days agoThe fasting regime reduces the development of liver cancer in mice with pre-existing liver...
A Single Meatless Meal Can Benefit Patients With Cirrhosis
Medscape· 3 days agoReplacing meat with plant-based proteins for just one meal reduced ammonia levels in patients with ...
Infected blood: Hundreds of victims living with undetected hepatitis C
BBC via Yahoo News· 3 days agoKnown as the "silent killer", hepatitis C may cause few symptoms initially, with early signs...
Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)
Morningstar· 3 days agoOvert hepatic encephalopathy is a complication of cirrhosis that can happen when the liver cannot filter toxins from the blood, and the toxins build up and reach the brain ...
Body found after fire burned Mesa home
Fox local via AOL· 2 days agoWhen the smoke cleared, a body was found inside. A life taken too soon, and taking with it, Perille's best friend. A place she’s sadly been before. "I...
AKERO THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC...
NBC 17 Raleigh· 24 hours agoKahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C....
How you could save £13k a year – and live longer
Daily Telegraph· 5 days agoAlcohol is also associated with more than 60 medical conditions, including mouth, throat, stomach, liver and breast cancers, high blood pressure, ...
Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at...
WPRI Providence· 4 days agoLipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that data from the Phase 2 study of LPCN 1148 has been selected for a late breaking oral presentation at the European ...
Contact Hagens Berman by June 25, 2024 Deadline to Join Class Action Against Akero Therapeutics...
Benzinga· 2 days agoSAN FRANCISCO, May 09, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Akero Therapeutics, Inc. (NASDAQ:AKRO) investors who suffered substantial losses to take action by submitting your losses now. Class Period: Sep. 13,
